Welcome to our dedicated page for Neuropace news (Ticker: NPCE), a resource for investors and traders seeking the latest updates and insights on Neuropace stock.
NeuroPace, Inc. (Nasdaq: NPCE) is a medical device company based in Mountain View, California, focused on transforming the lives of people living with epilepsy through its brain-responsive RNS System. The NeuroPace news feed on Stock Titan highlights company announcements that relate to financial performance, clinical evidence, regulatory milestones, reimbursement developments, and technology progress in neuromodulation and AI-enabled epilepsy care.
Investors and clinicians following NPCE can find updates on quarterly and annual financial results, revenue trends driven by RNS System sales, and guidance for future periods. NeuroPace frequently reports on gross margin performance, operating expenses, and strategic decisions such as focusing organizational efforts on its differentiated RNS System and treating certain distribution activities as discontinued operations for reporting purposes.
The news flow also includes clinical and regulatory developments, such as preliminary data from the NAUTILUS trial in antiseizure-medication resistant idiopathic generalized epilepsy (IGE), which has shown substantial median reductions in generalized tonic-clonic seizures and a favorable safety profile. NeuroPace provides updates on its Premarket Approval Supplement submissions to the U.S. Food and Drug Administration (FDA) for expanded RNS System indications, Breakthrough Device Designation for IGE, and progress in pediatric and AI software programs.
Another important category of news involves reimbursement and policy. NeuroPace has announced favorable Medicare Physician Fee Schedule and Outpatient Prospective Payment System decisions that increase reimbursement for RNS System implantation and replacement procedures and maintain stable inpatient classifications, developments the company describes as supportive of neurosurgeon adoption and patient access.
In addition, the NPCE news stream features participation in major medical and investor conferences, including the American Epilepsy Society Annual Meeting and large healthcare investment conferences, where NeuroPace presents Post-Approval Study data, NAUTILUS results, and demonstrations of NeuroPace AI and SeizureID tools. Users who want to monitor how clinical evidence, reimbursement, and AI-enabled tools evolve around the RNS System can review and revisit this news page for the latest company-issued information and event updates.
MOUNTAIN VIEW, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE) announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference. Management will present on September 13 at 12:20 p.m. Eastern Time. The event will be accessible via a live webcast and archived for at least 90 days on the company’s website.
NeuroPace focuses on transforming the lives of epilepsy patients with its RNS System, the first brain-responsive platform for real-time treatment, aiming to improve outcomes for those with drug-resistant epilepsy.
NeuroPace (Nasdaq: NPCE) reported Q2 2022 revenues of $10.2 million, down from $12.6 million year-over-year. The initial implant revenue was $8.0 million, a decrease from $9.2 million, primarily due to reduced patient volumes in Epilepsy Monitoring Units (EMUs) and COVID-19 cancellations. The net loss widened to $12.7 million from $8.5 million in the previous year. Guidance for 2022 forecasts total revenues between $43 million and $45 million, driven by new partnerships and an expanded sales team.
NeuroPace (Nasdaq: NPCE) has entered a commercialization agreement with DIXI Medical to exclusively market and sell its diagnostic electrodes for epilepsy in the U.S. This agreement takes effect on October 1, 2022. NeuroPace will promote stereoelectroencephalography (SEEG) electrodes, crucial for pinpointing seizure sources in patients with drug-resistant epilepsy. DIXI will support physicians with education and outreach, receiving an upfront payment and subsequent payments in 2023 and 2024. This partnership aims to enhance treatment options for epilepsy patients through combined expertise.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its second quarter financial results on August 11, 2022, after market close. The company focuses on improving the lives of individuals with epilepsy through its innovative RNS System, the first of its kind designed to provide real-time treatment at the seizure source. A conference call will follow at 1:30 PM PT, with a link available for investors to listen. Archived recordings will be accessible on the company’s website for at least 90 days.
MOUNTAIN VIEW, Calif., May 13, 2022 – NeuroPace, a medical device company focused on epilepsy treatment, will present at the 2022 RBC Capital Markets Global Healthcare Conference. CEO Mike Favet’s presentation is set for May 17 at 9:30 a.m. ET. A live webcast and archived recording will be accessible on the company’s website for 90 days. NeuroPace’s innovative RNS System offers personalized, real-time treatment for drug-resistant epilepsy, aiming to enhance care standards and improve outcomes for patients with various brain disorders.
NeuroPace, a medical device company focused on epilepsy, reported Q1 2022 revenue of $11.4 million, up from $11.2 million in Q1 2021. Initial implant revenue rose to $8.8 million, a significant increase from $8.1 million the previous year. However, replacement implant revenue dropped to $2.6 million from $3.1 million. The company experienced a net loss of $11.5 million, wider than the $8.8 million loss in Q1 2021. For 2022, they project revenue between $45 million and $48 million and a gross margin in the mid-70% range.
NeuroPace, Inc. has commenced the RESPONSE clinical trial, the first study assessing the efficacy of the RNS System for treating drug-resistant focal epilepsy in adolescents aged 12 to 17. Conducted at Westchester Medical Center, this pivotal study aims to confirm the system's safety and effectiveness as an adjunctive therapy. The RNS System is uniquely designed to deliver real-time treatment based on individual brain patterns, offering hope to over 1 million adolescents with epilepsy who are resistant to standard medication.
NeuroPace, Inc. (Nasdaq: NPCE) will release its financial results for Q1 2022 on May 12, 2022, after market close. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, accessible via phone or webcast on their website. NeuroPace specializes in medical devices for epilepsy treatment, with its RNS System being the first brain-responsive platform delivering timely, personalized therapies. This innovative approach aims to improve care for drug-resistant epilepsy patients and potentially others with brain disorders, enhancing treatment outcomes.
NeuroPace, Inc. (Nasdaq: NPCE) reported a 10% increase in total revenue, reaching $45.2 million for 2021, driven by a 20% rise in initial implant revenue. The fourth quarter revenue was $11.0 million, a 2% increase year-over-year. However, replacement implant revenue declined 19% in Q4. The company received FDA approval for a pivotal study in drug-resistant epilepsy and increased battery life for its RNS System. For 2022, guidance estimates total revenue between $45 million and $48 million.
NeuroPace, Inc. (Nasdaq: NPCE) announced it will report its financial results for Q4 and full year 2021 on March 10, 2022, post-market. A conference call will follow at 1:30 PM PT. Interested investors can join the call by dialing (844) 955-2173 or (914) 987-7949. CEO Mike Favet and other executives will also present at the SVB Leerink Global Healthcare Conference on February 17, 2022, at 10:00 AM PT. NeuroPace specializes in innovative medical devices for epilepsy treatment, with its RNS System being the first brain-responsive platform for real-time seizure management.